Company & Sponsor Intelligence
Biogen
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials17
Recruiting3
Completed9
Countries2
Therapeutic footprint
alsalzheimersepilepsymovement_disordersmultiple_sclerosisneuromuscularother_neurologyparkinsons
Indexed studies
NCT07221669A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
neuromuscular · United StatesPHASE3
neuromuscular · United StatesPHASE3
NCT02460094Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy
movement_disorders · United StatesPHASE1
movement_disorders · United StatesPHASE1
NCT04746976Study of Diroximel Fumarate in the Real-World Setting
multiple_sclerosis · United StatesTERMINATED
multiple_sclerosis · United StatesTERMINATED
NCT03689972A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
multiple_sclerosis · United StatesPHASE3
multiple_sclerosis · United StatesPHASE3
NCT07483632A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
multiple_sclerosis · PHASE3
multiple_sclerosis · PHASE3
NCT02623699An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)
als · United StatesPHASE3
als · United StatesPHASE3
NCT05798520A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
multiple_sclerosis · United StatesPHASE2
multiple_sclerosis · United StatesPHASE2
NCT02193074A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
neuromuscular · United StatesPHASE3
neuromuscular · United StatesPHASE3
NCT04924153A Natural History Study of Participants With Potassium Sodium-Activated Channel Subfamily T Member 1 (KCNT1)-Related Epilepsy
epilepsy · United StatesCOMPLETED
epilepsy · United StatesCOMPLETED
NCT04056689Study to Evaluate DNL151 in Subjects With Parkinson's Disease
parkinsons · United StatesPHASE1
parkinsons · United StatesPHASE1
NCT03283371Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
NCT03352557Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →